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Troost, Freddy J., Wim H. M. Saris, Guido R. M. M.
Haenen, Aalt Bast, and Robert-Jan M. Brummer. New
method to study oxidative damage and antioxidants in the
human small bowel: effects of iron application. Am J Physiol
Gastrointest Liver Physiol 285: G354–G359, 2003. First pub-
lished April 30, 2003; 10.1152/ajpgi.00422.2002.—Iron may
induce oxidative damage to the intestinal mucosa by its
catalyzing role in the formation of highly reactive hydroxyl
radicals. This study aimed to determine iron-induced oxida-
tive damage provoked by a single clinical dosage of ferrous
sulfate and to elucidate the antioxidant defense mechanisms
in the human small intestine in vivo. A double-lumen perfu-
sion tube was positioned orogastrically into a 40-cm segment
of the proximal small intestine in six healthy volunteers
(25  5 yr). The segment was perfused with saline and
subsequently with saline containing 80 mg iron as ferrous
sulfate at a rate of 10 ml/min. Intestinal fluid samples were
collected at 15-min intervals. Thiobarbituric acid reactive
substances concentrations as an indicator of lipid peroxida-
tion increased significantly from 0.07 M (range, 0–0.33 M)
during saline perfusion to 3.35 M (range, 1.19–7.27 M)
during iron perfusion (P  0.05). Nonprotein antioxidant
capacity increased significantly from 474 M (range, 162–
748 M) to 1,314 M (range, 674–1,542 M) (P  0.05).
These data show that a single dosage of ferrous sulfate
induces oxidative damage and the subsequent release of an
antioxidant in the small intestine in vivo in healthy volun-
teers.
duodenum; epithelium; lipid peroxidation; small intestine;
oxidative stress
THE PREVALENCE OF IRON DEFICIENCY anemia in Europe
and North America is 1% in adult males and 14% in
adult females (5). The usual treatment of iron defi-
ciency anemia involves oral iron supplementation with
ferrous salts. Ferrous salts, prescribed in amounts
195 mg of elemental iron/day divided over three sin-
gle dosages as ferrous sulfate, -fumarate or -gluconate,
respectively (7), are commonly preferred over ferric
salts because of their higher bioavailability. Oral fer-
rous iron therapy may, however, induce oxidative
stress due to its catalyzing role in Fenton chemistry,
resulting in the production of highly reactive hydroxyl
radicals (6, 23). They can react with any molecule in
their direct environment, resulting in a cascade of
reactions in which lipids, proteins, and DNA may get
damaged. Production of reactive oxygen species (ROS),
such as superoxide anion radicals, hydroxyl radicals,
and hydrogen peroxide, is normally balanced by the
antioxidant system. Excessive ROS production, how-
ever, induces a disturbance in the pro- and antioxidant
balance, resulting in oxidative damage.
Oral iron therapy, commonly indicated in people
with an elevated risk for developing iron deficiency,
such as children, adolescents, the elderly, (pregnant)
women, vegetarians, and athletes, may induce consid-
erable gastrointestinal (GI) side effects, such as nau-
sea, vomiting, heartburn, abdominal pain, and consti-
pation, in contrast to intravenous iron treatment (2).
Iron-induced oxidative damage in the intestine after
oral ingestion of iron supplements may, in part, be
responsible for these GI side effects. Additionally, oral
iron therapy in patients suffering from GI disorders
associated with an impaired mucosal or systemic anti-
oxidant capacity, such as inflammatory bowel disease
or celiac disease, may attribute to the development of
major oxidative damage (8, 13, 16, 19, 27).
Oral iron supplements were shown to aggravate lac-
tic acid-induced damage to the barrier function of the
small intestine epithelium (9) and to promote colon
tumorigenesis in mice (22) and inflammatory processes
in rats with colitis (1, 20). Moreover, electron paramag-
netic resonance spectroscopy in rats in vivo showed
that oral iron therapy with ferrous sulfate resulted in
iron-mediated oxidative stress through hydroxyl radi-
cals in the small intestine. This stress resulted in a
decrease in cell turnover, shortening of microvillus
height, and partial or complete erosion of the microvilli
in the duodenum (24). Epidemiological studies showed
a role of dietary iron in the development of colon cancer
(26). Additionally, ROS may induce development of
several forms of cancer (4, 18).
Because of the complexity of the direct measurement
of oxidative damage in the lumen of the human small
intestine in vivo, no data are available regarding the
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effects of clinically prescribed amounts of iron on oxi-
dative damage in the human intestine in vivo. Also,
little is known about the antioxidant defense mecha-
nisms against ROS production in the intestine. For this
purpose, we developed a perfusion technique to directly
quantify oxidative damage and antioxidant capacity in
vivo in the small intestine in healthy adults. This study
aimed to determine iron-induced oxidative damage
provoked by a single clinical dosage of ferrous sulfate
in the small intestine in humans and to obtain more
information about the antioxidant defense mecha-
nisms in the human small intestine in vivo.
MATERIALS AND METHODS
Subjects
Six healthy nonsmoking volunteers (25  5 yr, 3 males, 3
females) without a history of a GI disorder participated in the
present study. Volunteers were in good physical health at the
time of participation as checked by medical interview. All
subjects gave their written informed consent before partici-
pation. The study protocol was approved by the Ethics Com-
mittee of the University Hospital Maastricht, Maastricht,
The Netherlands.
Protocol
After an overnight fast, a perfusion catheter was ingested
orogastrically by each volunteer. The catheter consisted of
three silicon tubes connected to a rubber balloon on the distal
end of the catheter. One of the tubes called the sample port
had three small openings at 5 cm proximal of the distal end
of the catheter to enable fluid sampling from the small
intestine at the level of the distal end of the catheter. The
other two tubes were connected in an open loop with the
balloon to enable fluid and air transport in and out of the
balloon. A fourth lumen had a single opening at 45 cm from
the distal end. This port, referred to as the perfusion port,
served to administer a test solution directly into the duo-
denum.
After installation of the catheter tip into the stomach, the
rubber balloon was filled with 1.5 ml of mercury. Subjects
were instructed to remain in the supine position on the right
hand side with the upper body lifted 45° and the feet raised
20 cm until the balloon entered the duodenum. Positioning of
the catheter was checked with continuous pH-registration at
the tube tip. When the pH shifted from low (1–2.5) to4–6,
the mercury was aspirated and the balloon was subsequently
inflated with 15 ml of air. Subjects were instructed to stay in
the supine position on the back with the upper body lifted
45°. The catheter propagated subsequently by the peristaltic
movements of the GI tract. Catheter positioning was success-
ful when the perfusion port was placed 5–10 cm distally
from the pylorus. This was checked by a second pH-registra-
tion channel, which was located at 5 cm proximal from the
perfusion port. After positioning, the balloon was deflated to
stop it from progressing in the GI tract. Throughout the
experiment, the pH of the second pH channel was continu-
ously registered to ensure proper positioning of the perfusion
port. After the perfusion experiment, subjects removed the
catheter by pulling it gently.
Via the perfusion port, a saline solution was injected at 10
ml/min during 195 min. This period was necessary to reach
steady-state conditions as was observed in pilot experiments
(data not shown). Subsequently, a 300-ml saline solution
containing 80 mg elemental iron as ferrous sulfate (Merck,
Darmstadt, Germany) was perfused at 10 ml/min during 30
min. Finally, a saline solution was perfused again for 60 min
to rinse out the iron solution and intestinal secretions.
Intestinal fluid samples were obtained by using the lever
properties of the catheter. After an initial adaptation period
of 195 min, intestinal fluid content was levered through the
sample lumen into a beaker placed in melting ice. Intestinal
fluid excretions were pooled over 15-min intervals and stored
at 80°C until analysis.
Biochemical Analysis of Intestinal Fluid Samples
Thiobarbituric acid reactive substances assay. The deter-
mination of thiobarbituric acid reactive substances (TBARS)
was based on the formation of a colored adduct of malondi-
aldehyde (MDA) with 2-thiobarbituric acid (TBA). A 100 l
sample was added to 900 l of a reagent [containing 0.12 M
TBA, 0.32 M o-phosphoric acid, 0.68 mM butylated hydroxy-
toluene (BHT), and 0.01% (mass/vol) EDTA]. The mixture
was incubated for 1 h at 100°C in a water bath. After cooling,
the MDA-products were extracted with 500 l butanol. Then
30 l of the butanol layer were injected on an HPLC system
(Agilent, Palo Alto, CA) equipped with a fluorescence detec-
tor, set on an excitation wavelength of 532 nm and an
emission wavelength of 553 nm, and a Nucleosil C18 column
(150  3.2 mm) particle size 5 m (Supelco, PA). Samples
were eluted with 65% (vol/vol) 25 mM PBS (pH 4.8) and 35%
(vol/vol) methanol. A calibration curve was constructed by
using malonaldehyde bis(diethylacetal) as standard.
Antioxidant capacity assay. The antioxidant capacity as-
say was carried out as described previously (24a) with some
modifications. The 2,2-azinobis-(3-ethylbenzthiazoline-b-
sulfonate (ABTS ) was produced by incubating a solution of
0.23 mM ABTS and 2.3 mM 2,2-azobis-(2-amidinopropane)
hydrochloric acid (ABAP) in 100 mM sodium phosphate
buffer pH 7.4 at 70°C until the absorption of the solution at
734 nm was between 0.680 and 0.720. Deproteination was
done by mixing the sample with an equal volume of a solution
of 10% (wt/vol) TCA. In the reaction of antioxidants with the
blue/green ABTS , the blue/green color disappears. This
decolorization after 5 min is determined spectrophotometri-
cally at 734 nm. The reduction in absorbance is related to
that of Trolox, a synthetic, hydrophilic vitamin E analog,
which gives the Trolox equivalent antioxidant capacity
(TEAC) value. The TEAC value is calculated as molar Trolox
equivalents of the sample.
Glutathione assay. Total glutathione was determined by
using the recycling method (25). To 50 l of a 100 l sample
of a 0.4 mM NADPH/0.3 mM 5,5-dithiobis(2-nitrobenzoic
acid) solution in 143 mM PBS (pH 7.4) containing 6.3 mM
EDTA, is added in a 96-well plate. The reaction is then
started by adding 50 l of a solution containing 4 U/ml
glutathione reductase. The increase of the absorption (	A/
min) is followed for 2 min at 405 nm. The 	A/min of the
samples is compared with that of the calibrators and the
concentration of total glutathione is calculated.
Uric acid assay. Uric acid was determined in ultra filtrates
by using an HPLC method described previously (15) with
minor modifications. The sample was filtered over a 3-kDa
filter unit (Centrex UF 0.5; Schleicher & Schuell, Dassel,
Germany) by centrifugation for 45 min at 14,000 g and 4°C.
Then 25 l of the filtrates was analyzed on the HPLC. The
system (Agilent) consisted of a Hypersil BDS C-18 end-
capped column (125  4 mm), particle size 5 m (Agilent),
with a mobile phase of 5 mM sodium phosphate buffer (pH
3.3). Detection was performed by using a variable wave-
length detector set on a wavelength of 292 nm. Concentra-
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tions of uric acid were calculated by using a calibration curve
of uric acid.
Statistics
Differences were assessed by univariate ANOVA using
SPSS version 10.0 software. Differences were regarded as
significant when P  0.05. Multiple comparisons, used to
localize time differences, were adjusted with the least signif-
icant difference.
RESULTS
One to two hours after ingestion of the catheter, the
distal end of the catheter entered the duodenum. Cath-
eter positioning was completed within 5 to 8 h in all
volunteers.
TBARS levels were significantly higher at 15, 30, 45,
and 60 min after the start of the ferrous sulfate perfu-
sion compared with the baseline level measured at t 

0 (P  0.05) and returned to baseline levels after 90
min (Fig. 1).
The TEAC of the intestinal fluid was significantly
higher at 30 and 45 min after the start of the ferrous
sulfate perfusion compared with the baseline level
measured at t 
 0 (P  0.05) (Fig. 2).
Median alkaline phosphatase concentrations of the
perfusate samples did not differ significantly between
t 
 0 and t 
 30 min (502  377 and 510  363 U/l,
respectively).
Uric acid concentrations of the perfusate samples
were not significantly different from baseline during
the first 75 min after the start of the ferrous sulfate
perfusion (Table 1). At t 
 90, uric acid was statisti-
cally lower than baseline values (P  0.05).
Glutathione concentrations in the perfusate sam-
ples were under the detection limit of the equipment
(0.10 M).
DISCUSSION
The present study clearly shows that iron ingestion
in vivo induces intestinal oxidative damage as indi-
cated by the occurrence of lipid peroxidation. The mag-
nitude of the TBARS concentration in the intestinal
fluid samples as a result of iron ingestion was remark-
ably high. The TBARS assay was applied to estimate
MDA concentration, which is an end product of lipid
peroxidation. MDA is a well-accepted parameter of
oxidative damage (10). However, it is not specifically
produced as a result of free radicals attack, but may be
formed during the ex vivo sample incubation stage. To
prevent formation of MDA ex vivo, the chain-breaking
antioxidant BHT was added. The ability of BHT to
prevent TBARS formation during the analytical assay
was checked in ex vivo experiments with intestinal
fluid samples. In these experiments, we observed an
instantaneous rise in TBARS formation on iron addi-
tion, but BHT was effective in preventing TBARS for-
mation during the assay. Other possible analytical
shortcomings of the conventional TBARS-assay are
resolved by the use of the applied HPLC technique (11).
Therefore, in the present study TBARS provides an
accurate indicator of oxidative damage in vivo. The
Fig. 1. Thiobarbituric acid reactive substances (TBARS) concentra-
tions in intestinal perfusion samples, collected over 15-min intervals
after perfusion of a 40-cm segment in the proximal small intestine in
6 subjects. Baseline values at t 
 0 were obtained during saline
perfusion. Subsequently, saline containing 80 mg elemental iron as
ferrous sulfate was perfused for 30 min. Finally, saline was perfused
for 60 min at 10 ml/min (means  SE; differences vs. t 
 0 tested
with ANOVA; *P  0.05).
Fig. 2. Antioxidant capacity in intestinal perfusion samples, col-
lected over 15-min intervals after perfusion of a 40-cm segment in
the proximal small intestine in 6 subjects. Baseline values at t 
 0
were obtained during saline perfusion. Subsequently saline contain-
ing 80 mg elemental iron as ferrous sulfate was perfused for 30 min.
Finally saline was perfused for 60 min at 10 ml/min (means  SE;
differences vs. t 
 0 tested with ANOVA; *P  0.05).
Table 1. Uric acid concentrations in intestinal
perfusion samples pooled over 15-min periods
Time, min Uric acid, M
0 37.915.6
15 34.415.7
30 32.512.6
45 27.18.2
60 25.24.8
75 28.78.7
90 26.910.2
Values are means  SD; n 
 6.
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finding that antioxidant capacity increases in the lu-
men of the small intestine after an oxidative challenge
has not been described previously. The rapid and mas-
sive increase in antioxidant capacity of the intestinal
fluid samples indicates a powerful defense mechanism
of the small intestine against exogenous oxidants.
TBARS concentrations in the intestinal fluid sam-
ples after the iron challenge are roughly 3–5 times
higher than those observed in plasma in healthy
adults. This is a highly interesting finding in the view
of the dilution of the intestinal fluid samples. In pilot
experiments, we measured the dilution of the intesti-
nal fluid with the saline or saline/iron solution in the
intestinal segment by the addition of an inert marker,
lactulose, to the ingoing solution and subsequent mea-
surement of the lactulose concentration in the perfus-
ate samples. A dilution of 100-fold was found in all
samples. This dilution was constant throughout the
experiment (data not shown). In view of the fact that
sample dilution did not change during the experiment,
independently of the presence or absence of iron, intes-
tinal fluid dilution did not interfere with the results of
the study and hence, was not measured in the present
study.
On average, 15 mg of iron is present in the daily
diet. Approximately 2.5 mg iron entering the intestine
will be absorbed. Approximately 1% of the dietary iron
remains in the lumen in a form likely to participate in
free radical generation. During oral iron therapy in
adults using dosages of 60–195 mg iron/day, this pro-
portion remains the same, resulting in a much larger
amount of iron available for Fenton reactions. During
Fenton chemistry, ferrous iron catalyzes the formation
of hydroxyl radicals in the presence of superoxide an-
ion radicals and hydrogen peroxide, both produced as a
result of normal metabolism. Hydroxyl radicals are
highly reactive and can inflict damage to any biologic
molecule in its direct environment. The free electron
can transfer to another molecule and hence, initiate a
cascade of damaging reactions. Previously, it was
shown that the free radical generating capacity from
feces in healthy volunteers was markedly increased
after iron supplementation (19 mg/day iron as ferrous
sulfate for 14 day) (14). However, this was measured in
fecal samples ex vivo in an in vitro assay. This does not
necessarily reflect the conditions from the present
study in which the true effects of iron ingestion in the
small intestine in vivo were investigated. The results of
the present study confirm the finding that iron inges-
tion leads to an increase in free radical production in
the gut. The model used in the present study mimics
ingestion of an oral iron supplement, which dissolves in
the gastric juice and is subsequently released gradu-
ally into the small intestine.
From the data (Fig. 1) it is clear that oxidative
damage occurs immediately after iron administration
into the small intestine. This damage continues during
saline perfusion after the ferrous sulfate perfusion.
This is likely due to the low perfusion flow in the
experimental setup. After discontinuation of the iron
perfusion, it takes some time to rinse out all of the iron
and the intestinal juices secreted during the iron per-
fusion from the small intestine. After 60 min of saline
perfusion, no iron-induced rise in TBARS is observed
in the intestinal fluid samples anymore. These data are
in line with those of a rat study in which it was shown
that high dosages of iron supplements induce lipid
peroxidation in the colon (21). Any effects of iron sup-
plements in the small intestine were not investigated
in that study.
The lipid peroxidation observed in the present study
preceded a marked rise in TEAC (Fig. 2). From this, it
may be concluded that iron-induced oxidative stress
induces the release of an antioxidative component in
the small intestine. As for the TBARS concentrations,
the TEAC values are also remarkably high, especially
in view of the previously mentioned dilution of the
intestinal fluid samples with the ingoing solution. The
data of the present study indicate that a powerful
physiological mechanism in the small intestine pro-
tects against iron-induced oxidative damage. In view of
the fast release of the antioxidant(s), it is unlikely that
the iron-induced oxidative damage directly induced
production of an antioxidative agent, which is subse-
quently released into the lumen. It is more likely that
an antioxidant already present in a storage compart-
ment in the small intestine was released on oxidative
damage. In the present study, all samples were com-
pletely deproteinized during the TEAC assay. Sample
deproteination is routine practice during the TEAC
assay to reduce the analysis of variance. In pilot exper-
iments, we observed that sample deproteination did
not affect the average TEAC values compared with
duplicate nondeproteinized samples. Hence, the high
antioxidant capacity was exclusively caused by a non-
protein species. This excludes a role for enzymatic
antioxidants or metallothionines in the observed rise
in antioxidant capacity.
The rise in TEAC might be explained by lysis of
epithelial or mucosal cells. If the membranes of intact
cells were disrupted, its cellular content was excreted
into the lumen. As a result, the antioxidant capacity
would predominantly originate from the cytosolic anti-
oxidant capacity of the epithelial cells. However, this
would have been accompanied by a rise in total alka-
line phosphatase, which we did not observe. Also, re-
moval of intact epithelial cells present in the intestinal
fluid samples by centrifugation did not significantly
affect the antioxidant capacity of the samples (data not
shown). This suggests that the strong rise in TEAC
after iron-induced oxidative stress was not due to cell
lysis but was brought about by a specific antioxidant
mechanism.
Data regarding the nonprotein antioxidant capacity
of the small intestine are scarce. It was shown in a rat
study (17) that the small intestine has a powerful
reducing capacity, which is protective against triglyc-
eride hydroperoxides. The underlying mechanism or
the site of action (luminal, mucosal, or epithelial) was
not identified. In the present study, glutathione and
uric acid were determined in the intestinal fluid sam-
ples in an attempt to identify the origin of the rise in
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antioxidant capacity after iron perfusion. Due to the
intestinal fluid dilution by the perfusing solution, glu-
tathione concentrations were below the detection
threshold of the equipment used. Uric acid, a powerful
antioxidant present in lung- and intestine epithelial
lining fluid (12), was present in low amounts not af-
fected by the iron intervention. Vitamin C, present in
low amounts in most samples, did not show a correla-
tion with antioxidant capacity (data not shown).
Hence, neither of these antioxidants was responsible
for the rise in antioxidant capacity after the iron chal-
lenge in the present study.
The perfusion model to investigate oxidative stress
and antioxidant capacity in the human small intestine
enabled us to determine the effects of a prooxidative
agent over a standardized segment of the small intes-
tine. A major advantage of the technique is the rather
noninvasive protocol of the catheter positioning, be-
cause this occurred using normal peristaltic move-
ments. The technique is applicable to healthy volun-
teers as well as patients. The perfusion technique can
only be used to study a limited segment of the proximal
small intestine. Hence, results may not be directly
extrapolated to the entire small intestine. However,
due to a decreasing nutrient concentration along the
small intestine, nutrient-associated oxidative damage
probably takes place predominantly in the proximal
small intestine. The rate of perfusion needs to be as low
as possible to avoid effects of the perfusion experiment
on normal functioning of the small intestine. Because
of the low perfusion flow, it is not possible to monitor
acute, short-term responses in the small intestine. Ad-
ditionally, sampling occurs at 15-min intervals to en-
sure sufficient sample collection during each collection
interval. The perfusion technique provides the unique
feature to study oxidative damage and antioxidant
capacity in secretions of the small intestine in vivo in
humans under strictly standardized conditions. This
model is applicable to a variety of intestinal disorders
associated with a disturbance in the equilibrium be-
tween oxidative stress and the antioxidant defense
network. Increased oxidative stress occurs in acute and
chronic inflammation, certain drugs, and nutrients.
Decreased antioxidant capacity may be present in dis-
orders of mucosal integrity and chronic malabsorption
disorders associated with antioxidant deficiencies (8).
A disturbance in the equilibrium between oxidative
stress and the antioxidant defense network in the
small intestine may be an important factor in the
pathophysiology of these disorders. Additionally, the
perfusion technique can be used to evaluate the effi-
ciency of nutritional antioxidant interventions in re-
storing a sufficient antioxidant network against oxida-
tive attack in the small intestine.
Iron ingestion induced Fenton-driven oxidative
stress in the human small intestine, followed by a
massive rise in total antioxidant capacity in the lumen.
This rise may reflect the release of a powerful, yet
unidentified, nonprotein antioxidant. Future work
should focus on identification of this antioxidant and
on the possibilities to increase the antioxidant capacity
against oxidative stress with nutritional interventions
in disorders related to a high intestinal oxidative stress
or a low intestinal antioxidant defense network.
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